

DIASORIN S.P.A. – UPDATE 2026 ANNUAL CALENDAR OF CORPORATE EVENTS*

Saluggia, October 5, 2026 – Updating the notice published on December 22, 2025, please find below the the new scheduled date for the approval of the Third Quarter 2026 results approval.

Board of Directors

November 12, 2026	Third Quarter 2026 results approval
--------------------------	--

* Indicative date subject to change. Any changes will be timely communicated.

The conference call for the presentation of the financials results to the investors will take place, as in the past, on the same day of the approval by the Board of Directors. The timing will be communicated as soon as scheduled.

About Diasorin

Headquartered in Italy and listed on Euronext Milan, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and has also been active in the Life Science business since 2021. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates across 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offering, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS**Margherita Sacerdoti**

Senior Director, Investor Relations & ESG

margherita.sacerdoti@diasorin.com